decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / HUMAN_TUMOR_STEM_CELL_DRUG_SENSITIVITY_ASSAYS
Subscribe or sign in to view the full article.
Article Overview
This article explains Medicare’s coverage position for human tumor stem cell drug sensitivity assays and a related fluorescent assay used in cancer chemosensitivity testing. It is relevant to providers, laboratories, coders, and compliance staff who need to understand how the National Coverage Determinations Manual classifies these services and why they are addressed in coverage policy. The article focuses on the testing concept, the Medicare coverage status, and the policy context rather than coding mechanics.
Why This Topic Matters
Coverage policy determines whether a service is considered payable under Medicare, making this important for billing, documentation review, and compliance planning in oncology-related laboratory testing.
Article Sections
-
Human Tumor Stem Cell Drug Sensitivity Assays
Introduces the assay category and describes its general purpose in evaluating tumor response to anticancer drugs. Summarizes the Medicare coverage status discussed in the policy.
-
Fluorescent Cytoprint Assay
Describes a related cancer chemosensitivity testing approach and its general testing format. Summarizes the policy treatment of this assay within the manual.
What You Will Learn
- The general subject matter addressed by the coverage policy
- How the article frames Medicare coverage status for the testing topics discussed
- The broader clinical and laboratory context of tumor drug sensitivity and chemosensitivity assays
- Which policy manual section covers these assays
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Oncology laboratories
- Physicians and clinicians
- Coverage and reimbursement analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com